Table of Contents
Chapter 1. Metagenomics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information analysis
1.2.2. Market formulation & data visualization
1.2.3. Data validation & publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Metagenomics Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Metagenomics Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Declining expenses of sequencing
3.3.2. Developments in biotechnology & bioinformatics techniques
3.3.3. Rising interest in microbial screening for different investigations
3.3.4. Emergence of new fields in genomics that complement metagenomics
3.4. Market Restraint Analysis
3.4.1. Limited accessibility to computation and different analytic tools
3.4.2. High overall cost of metagenomics
3.5. Business Environment Analysis
3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.5.2. Porter’s Five Forces Analysis
3.6. COVID – 19 Impact Analysis
Chapter 4. Metagenomics Market: Product Business Analysis
4.1. Segment Dashboard
4.2. Global Metagenomics Market Product Movement Analysis
4.3. Global Metagenomics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.3.1. Kits and Reagents
4.3.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.3.2. Sequencing & Data Analytics Services
4.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
4.3.3. Software
4.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 5. Metagenomics Market: Technology Business Analysis
5.1. Segment Dashboard
5.2. Global Metagenomics Market Technology Movement Analysis
5.3. Global Metagenomics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.3.1. Shotgun Sequencing
5.3.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.3.2. 16S Sequencing
5.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.3.3. Whole Genome Sequencing
5.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
5.3.4. Others
5.3.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 6. Metagenomics Market: Workflow Business Analysis
6.1. Segment Dashboard
6.2. Global Metagenomics Market Workflow Movement Analysis
6.3. Global Metagenomics Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
6.3.1. Pre-sequencing
6.3.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.3.2. Sequencing
6.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
6.3.3. Data Analysis
6.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 7. Metagenomics Market: Application Business Analysis
7.1. Segment Dashboard
7.2. Global Metagenomics Market Application Movement Analysis
7.3. Global Metagenomics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
7.3.1. Environmental
7.3.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.3.2. Clinical Diagnostics
7.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.3.3. Drug Discovery
7.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.3.4. Biotechnology
7.3.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.3.5. Food & nutrition
7.3.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
7.3.6. Others
7.3.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Regional Dashboard
8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
8.3. North America
8.3.1. North America Metagenomics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.2. U.S.
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. U.S. Market Estimates and Forecasts 2018 To 2030 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4. Europe
8.4.1. Europe Metagenomics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. UK Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.4. Spain
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.5. France
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.6. Italy
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Asia Pacific Metagenomics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.5.2. JAPAN
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.5.7. Australia
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6. Latin America
8.6.1. Latin America Metagenomics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.6.3. Mexico
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Mexico Metagenomics Market, 2018 – 2030 (USD Million)
8.6.4. Argentina
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7. MEA
8.7.1. MEA Metagenomics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. UAE Market Estimates And Forecasts 2018 To 2030 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2023
9.4. Participant’s Overview
9.4.1. Bio-Rad Laboratories, Inc.
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Illumina, Inc.
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. PerkinElmer, Inc
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Thermo Fisher Scientific, Inc
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Novogene Co., Ltd.
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Promega Corporation
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. QIAGEN
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Takara Bio, Inc.
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Oxford Nanopore Technologies plc.
9.4.9.1. Overview
9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. F. Hoffmann-La Roche Ltd.
9.4.10.1. Overview
9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
|